Literature DB >> 14601754

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

Peter B Gilbert1, Ronald J Bosch, Michael G Hudgens.   

Abstract

Vaccines with limited ability to prevent HIV infection may positively impact the HIV/AIDS pandemic by preventing secondary transmission and disease in vaccine recipients who become infected. To evaluate the impact of vaccination on secondary transmission and disease, efficacy trials assess vaccine effects on HIV viral load and other surrogate endpoints measured after infection. A standard test that compares the distribution of viral load between the infected subgroups of vaccine and placebo recipients does not assess a causal effect of vaccine, because the comparison groups are selected after randomization. To address this problem, we formulate clinically relevant causal estimands using the principal stratification framework developed by Frangakis and Rubin (2002, Biometrics 58, 21-29), and propose a class of logistic selection bias models whose members identify the estimands. Given a selection model in the class, procedures are developed for testing and estimation of the causal effect of vaccination on viral load in the principal stratum of subjects who would be infected regardless of randomization assignment. We show how the procedures can be used for a sensitivity analysis that quantifies how the causal effect of vaccination varies with the presumed magnitude of selection bias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14601754     DOI: 10.1111/1541-0420.00063

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  45 in total

1.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

2.  Principal stratification and attribution prohibition: good ideas taken too far.

Authors:  Marshall Joffe
Journal:  Int J Biostat       Date:  2011-09-14       Impact factor: 0.968

3.  THE POTENTIAL FOR BIAS IN PRINCIPAL CAUSAL EFFECT ESTIMATION WHEN TREATMENT RECEIVED DEPENDS ON A KEY COVARIATE.

Authors:  Corwin M Zigler; Thomas R Belin
Journal:  Ann Appl Stat       Date:  2011       Impact factor: 2.083

4.  On the estimation of a binary response model in a selected population.

Authors:  Francesco Claudio Stingo; Elena Stanghellini; Rosa Capobianco
Journal:  J Stat Plan Inference       Date:  2012-10-01       Impact factor: 1.111

5.  Augmented designs to assess immune response in vaccine trials.

Authors:  Dean Follmann
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

6.  Nonparametric Bounds and Sensitivity Analysis of Treatment Effects.

Authors:  Amy Richardson; Michael G Hudgens; Peter B Gilbert; Jason P Fine
Journal:  Stat Sci       Date:  2014-11       Impact factor: 2.901

7.  ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Authors:  Li Qin; Peter B Gilbert; Dean Follmann; Dongfeng Li
Journal:  Ann Appl Stat       Date:  2008-03       Impact factor: 2.083

8.  Causal Vaccine Effects on Binary Postinfection Outcomes.

Authors:  Michael G Hudgens; M Elizabeth Halloran
Journal:  J Am Stat Assoc       Date:  2006-03       Impact factor: 5.033

9.  Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

Authors:  Dean Follmann; Ann Duerr; Stephen Tabet; Peter Gilbert; Zoe Moodie; Patricia Fast; Massimo Cardinali; Steve Self
Journal:  J Acquir Immune Defic Syndr       Date:  2007-01-01       Impact factor: 3.731

Review 10.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.